|
1
|
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis.
|
Circulation
|
2003
|
3.45
|
|
2
|
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.
|
Clin Pharmacol Ther
|
2002
|
1.63
|
|
3
|
Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
|
J Pediatr Hematol Oncol
|
2003
|
1.43
|
|
4
|
Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial.
|
J Clin Oncol
|
2002
|
1.06
|
|
5
|
Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control study.
|
BMC Cardiovasc Disord
|
2011
|
0.95
|
|
6
|
Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
|
J Vasc Interv Radiol
|
2002
|
0.91
|